Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Parkinson's Disease
100%
Leucine-rich Repeat Kinase 2 (LRRK2)
65%
Morphine
41%
G2019S mutation
35%
Mutation Carriers
35%
G2019S
31%
COVID-19
31%
Analgesic Tolerance
28%
Ashkenazi Jews
28%
Deep Brain Stimulation
26%
Male Mice
26%
Female Mice
26%
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
26%
Patients with Parkinson's Disease
22%
Endogenous Opioids
22%
Engel Class
19%
Glucocerebrosidase mutations
18%
Jumping Frequency
18%
Epilepsy
17%
Antiepileptic Drugs
17%
Neuropsychological Assessment
16%
Parkinson Patients
16%
Glucocerebrosidase
16%
Disease Phenotype
16%
Epilepsy Surgery
16%
Inbred Strains
15%
Parkinson
15%
Surgical Management
14%
Morphine Dependence
13%
Naloxone-precipitated Withdrawal
13%
Cognitive Functioning
13%
Genetic Variation
13%
Lessons Learned
13%
Multilobar Resection
13%
Gait
13%
Global Pandemic
13%
Morphine Withdrawal
13%
Teleneurology
13%
Randomized Placebo-controlled Trial
13%
Non-manifesting Carriers
13%
Donepezil
13%
Antidepressant Use
13%
Childhood Stroke
13%
Diffusion Tensor Imaging
13%
Gray Matter Volume
13%
Impulsivity
13%
L-DOPA
13%
Medial Prefrontal Cortex (mPFC)
13%
Meningioma
13%
Voxel-based Morphometry
13%
Neuroscience
Parkinson's Disease
88%
Morphine
65%
Deep Brain Stimulation
39%
Naloxone
37%
Leucine Rich Repeat Kinase 2
26%
Epilepsy
26%
Physical Dependence
20%
Glucosylceramidase
19%
Genetics
17%
Subthalamic Nucleus
17%
L-DOPA
15%
Morphine Addiction
13%
Meningioma
13%
Diffusion Tensor Imaging
13%
Impulsivity
13%
Morphine Withdrawal
13%
Voxel-Based Morphometry
13%
Amobarbital
13%
Fluorodopa
13%
Donepezil
13%
Placebo
13%
Quantitative Trait Locus
13%
Antidepressant
13%
Nociceptin
13%
Cognitive Effect
13%
Ventromedial Prefrontal Cortex
13%
Autism
13%
Neurotrauma
13%
Traumatic Brain Injury
13%
Olfaction
11%
Gait
10%
Leucine
9%
Positron Emission Tomography
9%
Kinase
9%
Ultrasonography
9%
Mood Disorder
9%
Gray Matter Volume
7%
Dementia with Lewy Bodies
6%
Parkinsonism
6%
Neuropsychological Test
5%
Cognitive Disorders
5%
Executive Function
5%